Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Terminated 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Leukemia, Myeloid, Chronic-Phase 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Gastrointestinal Stromal Tumors 2Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) 1Philadelphia Chromosome 1Neoplasm, Residual 1Leukemia, Biphenotypic, Acute 1Hypereosinophilic Syndrome 1Head and Neck Neoplasms 1Burkitt Lymphoma 1

Interventions

venetoclax 1ruxolitinib 1pevonedistat 1Imatinib Mesylate 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Hypereosinophilic Syndrome × Imatinib Mesylate × Clear all
NCT00044304 2026-03-16

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
70 enrolled
Myeloid

Hypereosinophilic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡